Premium
Association of HPC2/ELAC2 and RNASEL non‐synonymous variants with prostate cancer risk in African American familial and sporadic cases
Author(s) -
Robbins Christiane M.,
Hernandez Wenndy,
Ahaghotu Chiledum,
Bennett James,
Hoke Gerald,
Mason Terry,
Pettaway Curtis A.,
Vijayakumar Srinivasan,
Weinrich Sally,
FurbertHarris Paulette,
Dunston Georgia,
Powell Isaac J.,
Carpten John D.,
Kittles Rick A.
Publication year - 2008
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20841
Subject(s) - prostate cancer , biology , haplotype , allele frequency , population , population stratification , odds ratio , allele , medicine , cancer , genetics , genotype , single nucleotide polymorphism , gene , environmental health
The RNASEL and HPC2/ELAC2 genes have been implicated in hereditary prostate cancer. Further assessment of the role of these genes in sporadic prostate cancer in African American men (AAM) is warranted. Methods Genotyping of HPC2/ELAC2 variants (S217L, A541T), along with RNASEL variants (R462Q and E541D) was completed in 155 African American sporadic and 88 familial prostate cancer cases, and 296 healthy male controls. Logistic regression analysis was performed and odds ratios (OR) were calculated, while correcting for both age and population stratification using admixture informative markers. Results The HPC2/ELAC2 217L allele was significantly associated with risk of prostate cancer when taking all cases into account (OR = 1.6; 1.0–2.6; P = 0.03). The RNASEL 541D allele was associated with a decrease in risk of prostate cancer in sporadic cases (OR = 0.4; 0.2–0.8; P = 0.01). We did not detect an association between prostate cancer risk and the RNASEL R462Q variant. Results from haplotype analyses of the two RNASEL variants revealed highly significant differences in haplotype allele frequencies between cases and controls suggesting a synergistic effect at the RNASEL locus. One haplotype in particular (462R–541D) is far more frequent in our control population and shows a strong protective effect against prostate cancer (OR = 0.47, P = 8.1 × 10 −9 ). Conclusions These results suggest that HPC2/ELAC2 and RNASEL may play a role, however minor, in prostate cancer risk among AAM.